19 October 2017Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

11 July 2018 The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Americas

FTC antitrust charges against Impax dismissed

25 May 2018 A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.

Americas

Impax to divest 10 products amid acquisition by Amneal

30 April 2018 The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Amneal and Impax merge to become ‘fifth largest’ generics company

More on this story

Editor's picks

Editor's picks

More features